Influence of phenotype and pharmacokinetics on β-blocker drug target pharmacogenetics

Pharmacogenomics Journal

Volumn 6, Issue 3, 2006, Pages 174-178

  Beitelshees, A L ^a   Zineh, I ^a   Yarandi, H N ^b,c   Pauly, D F ^d   Johnson, J A ^a,d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF NURSING   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

1 adrenergic receptor polymorphisms; ADRB1; Heart rate; Metoprolol; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCINE; METOPROLOL; SERINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CHRONOTROPISM; CODON; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG TARGETING; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREADMILL EXERCISE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ALLELES; ANTIHYPERTENSIVE AGENTS; EXERCISE; GENE FREQUENCY; HEART RATE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; METOPROLOL; PHARMACOGENETICS; PHENOTYPE;

EID: 33744543964     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500354     Document Type: Article

References (23)

1. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274: 12670-12674.
2. Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155-160.
3. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52.
4. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74: 372-379.
5. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73: 366-371.
6. La Rosee K, Huntgeburth M, Rosenkranz S, Bohm M, Schnabel P. The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics 2004; 14: 711-716.
7. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77: 127-137.
8. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 2005; 15: 227-234.
9. Xie HG, Dishy V, Sofowora G, Kim RB, Landau R, Smiley RM et al. Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11: 191-197.
10. Buscher R, Belger H, Eilmes KJ, Tellkamp R, Radke J, Dhein S et al. In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans. Pharmacogenetics 2001; 11: 199-205.
11. Ranade K, Jorgenson E, Sheu WH, Pei D, Hsiung CA, Chiang FT et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70: 935-942.
12. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (London) 2000; 99: 233-238.
13. Humma LM, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL et al. Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol 2001; 88: 1034-1037.
14. de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, Foucher-Hossein C et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 2005; 15: 137-142.
15. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2005: 1-6, [E-Pub ahead of print].
16. Monteleone P, Santonastaso P, Tortorella A, Favaro A, Fabrazzo M, Castaldo E et al. Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa. Mol Psychiatr 2005; 10: 716-718.
17. Yang L, Wang YF, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatr 2004; 43: 1154-1158.
18. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005; 30: 1719-1723.
19. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394-1399.
20. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76: 536-544.
21. Johnson JA, Akers WS, Miller ST, Applegate WB. Metoprolol minimizes nighttime blood pressure dip in hypertensive black males. Am J Hypertens 1995; 8: 254-259.
22. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996; 24: 350-355.
23. Maqbool A, Hall AS, Ball SG, Balmforth AJ. Common polymorphisms of beta1-adrenoceptor: Identification and rapid screening assay. Lancet 1999; 353: 897.